AstraZeneca launches Clinical Data and Insights division in India

October 20, 2021

Expands its footprint in the country 

India

healthysoch

New Delhi, October 20, 2021:

AstraZeneca India Private Limited, the Global Capability Centre (GCC) of AstraZeneca, a leading science-led biopharmaceutical company, launched a clinical data and insights division in India to further strengthen its global presence, and for the management of data-related aspects of its clinical trials. The Clinical Data & Insights team in Bengaluru, India, is a critical advancement to support a growing global portfolio, and build on internal data expertise. With the centre started its operations recently, the team will continue to expand by sourcing the right talent and resource for future needs.

Reporting into Development Operations in Biopharmaceuticals R&D, the Clinical Data & Insights (CDI) team is responsible for the management of data-related aspects of AstraZeneca’s clinical trials, excluding analysis and reporting. CDI division works across therapy areas and portfolios, supporting early and late-stage clinical programmes from Phase 1 to Phase 3 with an integrated end-to-end approach for clinical data, analytics, insights and risk management. Currently a 30-member team, the division is expected to grow to a 100+ member strong team by 2022.

Commenting on the launch of the CDI division in India, Siva Padmanabhan, Managing Director, AstraZeneca India Private Limited, said, “The role of GCCs in the overall growth of the parent organisation is witnessing a shift. Over the last decade, GCCs in India are undertaking more strategic and transformative work critical to the success of the organisation. India has seen a constant uptick in investment in areas such as Business Services, Engineering, Digital, IT, R&D and Product Development from global Fortune-500 companies. AstraZeneca in India is no different – since its inception, AZIPL has supported the global organisation with various services spanning IT, Business Services and R&D from our centres in Chennai and Bengaluru, on transformative projects. AstraZeneca’s decision to set up the CDI division in India is only a natural progression of this, to further capitalise on the extensive talent pool in the country.”

AstraZeneca CDI’s current footprint includes over 400 employees and approximately 700 data management professionals in vendor partnerships across six countries. They are now embedding data science and Artificial Intelligence (AI) across R&D centres to enable their data teams to push the boundaries of science to deliver life-changing medicines.

Commenting on setting up a CDI division in India, Natalie Fishburn, Vice President, Global Head of Clinical Data & Insights, AstraZeneca, said, “Clinical data and insight solutions enable pharmaceutical organisations such as ours to gain in-depth visibility into the patient’s journey by extracting actionable insights from disparate data sources. The establishment of the CDI division in India is key to our strategic vision of being industry leaders in this space. The way in which we manage data is evolving, and we are growing and expanding our capabilities to be ready for the future. In addition, the fact that the Indian market has grown significantly by offering a large talent pool, many of whom have over 10 years of experience, has further motivated us to set up this division in India.”

healthysoch

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Health Tips

Dr. T S Kler Padma Bhushan Awardee
MD, DM, MRCP, FRCP(U.K), FACC, D.Sc
Chairman – Fortis Heart Institute Gurugram

Precautions to avoid Corona Virus:

  1. Stay home as far as possible.
  2. Wash hands with soap and water frequently.
  3. Keep distance from people even your home members.
  4. Keep atleast 1-2 metres away from anybody coughing.
  5. Don’t touch your face, nose and mouth.

 

Dr. K.K Says

Archives

MonTueWedThuFriSatSun
    123
45678910
18192021222324
25262728293031
       
   1234
567891011
12131415161718
26272829   
       
891011121314
293031    
       
    123
45678910
11121314151617
25262728293031
       
  12345
6789101112
13141516171819
27282930   
       
      1
2345678
9101112131415
16171819202122
3031     
     12
17181920212223
24252627282930
31      
   1234
567891011
12131415161718
2627282930  
       
1234567
891011121314
22232425262728
293031    
       
     12
3456789
17181920212223
24252627282930
       
  12345
6789101112
       
  12345
13141516171819
2728     
       
      1
9101112131415
3031     
   1234
567891011
       
282930    
       
    123
45678910
       
  12345
27282930   
       
      1
3031     
    123
11121314151617
       
28      
       
2930     
       
    123
       
       
       
      1
9101112131415
3031     
     12
3456789
10111213141516
17181920212223
242526272829 
       
  12345
13141516171819
2728293031  
       
      1
23242526272829
3031     
    123
       
    123
25262728   
       
78910111213
28293031   
       
293031    
       
14151617181920
28293031   
       
   1234
567891011
       
   1234
567891011
262728    
       
891011121314
293031    
       
    123
18192021222324
25262728293031
       
  12345
27282930   
       
      1
2345678
16171819202122
3031     
    123
45678910
18192021222324
       
28293031   
       
     12
31      
   1234
       
  12345
6789101112
       
HealthySoch

Don't Miss

COVID-19: Myth vs. Facts

Media reports claiming that Expired Vaccines are being Administered in

Consultations on design of Pradhan Mantri Swasthya Suraksha Mission (PMRSSM) with key stakeholders 

New Delhi, May 3, 2018: Shri Indu Bhushan, CEO, Ayushman